Kiora Pharmaceuticals (KPRX) to Post Quarterly Earnings on Friday

Kiora Pharmaceuticals (NASDAQ:KPRX) is expected to be posting its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect Kiora Pharmaceuticals to post earnings of ($0.47) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its earnings results on Friday, May 8th. The company reported ($0.58) EPS for the quarter, hitting the consensus estimate of ($0.58).

Kiora Pharmaceuticals Price Performance

KPRX stock opened at $2.47 on Wednesday. The business has a fifty day moving average price of $2.58 and a 200 day moving average price of $2.36. Kiora Pharmaceuticals has a fifty-two week low of $1.76 and a fifty-two week high of $3.01. The stock has a market capitalization of $10.94 million, a price-to-earnings ratio of -0.91 and a beta of -0.38.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Kiora Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KPRX. Two Sigma Investments LP acquired a new stake in shares of Kiora Pharmaceuticals in the 3rd quarter valued at $33,000. Renaissance Technologies LLC lifted its stake in shares of Kiora Pharmaceuticals by 71.0% during the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after acquiring an additional 8,800 shares during the period. Citadel Advisors LLC bought a new position in Kiora Pharmaceuticals in the third quarter valued at about $125,000. Alyeska Investment Group L.P. bought a new position in Kiora Pharmaceuticals in the fourth quarter valued at about $152,000. Finally, DRW Securities LLC increased its position in Kiora Pharmaceuticals by 199.2% in the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after purchasing an additional 73,417 shares during the period. Institutional investors and hedge funds own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.